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Abstract. 
 
Regulation of vascular homeostasis depends 
upon collaboration between cells of the vessel wall and 
blood coagulation system. A direct interaction between 
integrin 
 
a
 
V
 
b
 
3
 
 on endothelial cells and smooth muscle 
cells and prothrombin, the pivotal proenzyme of the 
blood coagulation system, is demonstrated and activa-
tion of the integrin is required for receptor engage-
ment. Evidence that prothrombin is a ligand for 
 
a
 
V
 
b
 
3 
 
on these cells include: (
 
a
 
) prothrombin binds to purified 
 
a
 
V
 
b
 
3
 
 via a RGD recognition specificity; (
 
b
 
) prothrom-
bin supports 
 
a
 
V
 
b
 
3
 
-mediated adhesion of stimulated en-
dothelial cells and smooth muscle cells; and (
 
c
 
) endo-
thelial cells, either in suspension and in a monolayer, 
recognize soluble prothrombin via 
 
a
 
V
 
b
 
3
 
. 
 
a
 
V
 
b
 
3
 
-mediated 
cell adhesion to prothrombin, but not to fibrinogen,
required
 
 
 
activation of the receptor. Thus, the function-
ality of the 
 
a
 
V
 
b
 
3
 
 receptor is ligand defined, and
prothrombin and fibrinogen represent activation-
dependent and activation-independent
 
 
 
ligands.
Activation of 
 
a
 
V
 
b
 
3 
 
could be induced not only by model 
agonists, PMA and Mn
 
2
 
1
 
, but also by a physiologically 
relevant agonist, ADP. Inhibition of protein kinase C 
and calpain prevented activation of 
 
a
 
V
 
b
 
3 
 
on vascular 
cells, suggesting that these molecules are involved in 
the inside-out signaling events that activate the integrin. 
The capacity of 
 
a
 
V
 
b
 
3
 
 
 
to interact with prothrombin may 
play a significant role in the maintenance of hemostasis; 
and, at a general level, ligand selection by 
 
a
 
V
 
b
 
3
 
 may be 
controlled by the activation state of this integrin.
Key words: integrins ¥ endothelial cells ¥ smooth 
muscle cells ¥ cell adhesion ¥ ligands
 
T
 
he
 
 adhesive properties of vascular cells and the in-
teraction of these cells with the blood coagulation
system are intimately linked to the maintenance of
vascular homeostasis. Whereas the endothelial cell lining
of blood vessels is usually nonthrombogenic, vascular in-
jury or the local generation of chemokines changes the
surface properties such that the endothelial cells can ini-
tiate and efficiently propagate blood coagulation (Scarpati
and Sadler, 1989; Stern et al., 1991; Bombeli et al., 1997).
The culmination of these events is the activation of
prothrombin to thrombin at the endothelial cell surface
(Sueishi et al., 1995). In concert with changes in procoagu-
lant activity, the adhesive properties of the endothelial
cells are often altered. Expression and activation of a vari-
ety of adhesion receptors occur at the surface of stimu-
lated endothelial cells (Pober and Cotran, 1990). Such
changes are not restricted to endothelial cells; vascular
smooth muscle cells also respond to injury and stimulation
by changing their adhesive properties, such that they be-
come migratory, and by expressing procoagulant activity
on their cell surface (Taubman, 1993; Sueishi et al., 1995).
Thus, the adhesive properties of vascular cells and their
capacity to support prothrombin activation are intimately
interwoven.
Recently, we have identified a previously unrecognized
linkage between the major circulating cellular participant
in thrombus formation, the platelet, its adhesive proper-
ties and thrombin generation by demonstrating that pro-
thrombin serves as a ligand for the major integrin on the
platelet surface, 
 
a
 
IIb
 
b
 
3 
 
(Byzova and Plow, 1997). Pro-
thrombin binds to 
 
a
 
IIb
 
b
 
3
 
 on resting platelets in a specific,
saturable, and divalent cation-dependent manner. This in-
teraction accelerates prothrombin activation to thrombin,
but thrombin itself does not bind to the receptor. Recogni-
tion of prothrombin by 
 
a
 
IIb
 
b
 
3
 
 is mediated by an Arg-Gly-
Asp (RGD)
 
1
 
 recognition specificity; RGD-containing pep-
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tides, which inhibit the binding of many ligands to 
 
a
 
IIb
 
b
 
3
 
,
also block prothrombin binding to the receptor. 
 
a
 
V
 
b
 
3
 
 con-
tains the same 
 
b 
 
subunit and an homologous 
 
a 
 
subunit as
 
a
 
IIb
 
b
 
3
 
 and plays a prominent role in vascular cell adhesion
and migration. Cultured human umbilical vein endothelial
cells (HUVEC) express 
 
a
 
V
 
b
 
3
 
 as a major cell surface mole-
cule (Cheresh, 1987) on both their luminal and basolateral
surfaces (Conforti et al., 1992) and in endothelial cellÐcell
contacts (Glass and Kreisberg, 1993), and nonactivated
SMC derived from large vessels also express 
 
a
 
V
 
b
 
3 
 
(Brown
et al., 1994). The binding of many ligands to 
 
a
 
V
 
b
 
3
 
 is medi-
ated by a RGD recognition specificity, and 
 
a
 
V
 
b
 
3
 
 and 
 
a
 
IIb
 
b
 
3
 
share many common ligands, including von Willebrand
factor, fibrinogen, fibronectin, and thrombospondin (Ruos-
lahti, 1996; Yamada, 1991).
In this study, we have sought to determine whether pro-
thrombin can serve as a ligand for 
 
a
 
V
 
b
 
3
 
 on vascular endo-
thelial cells and smooth muscle cells. Our consideration of
this possibility also was stimulated by the work of Bar-
Shavit et al. (1991, 1993), who reported that cleavage
products of thrombin or denatured thrombin, but not
native thrombin, supported the adhesion of HUVEC in
a RGD-dependent manner. In addition, recent studies
showing prothrombin is deposited in the vessel wall at
sites of injury (Hatton et al., 1995) and is synthesized by
smooth muscle cells (McBane et al., 1997) adds further bi-
ological relevance to the role of prothrombin as a poten-
tial 
 
a
 
V
 
b
 
3
 
 ligand. Here, we demonstrate that prothrombin
can serve not only as an adhesive ligand for 
 
a
 
V
 
b
 
3
 
 but also
as a soluble ligand for the receptor. However, the interac-
tions of prothrombin with 
 
a
 
V
 
b
 
3
 
 and 
 
a
 
IIb
 
b
 
3
 
 are fundamen-
tally different: engagement of prothrombin by 
 
a
 
V
 
b
 
3
 
 on
vascular cells requires receptor activation, whereas its
binding to 
 
a
 
IIb
 
b
 
3
 
 on platelets does not (Byzova and Plow,
1997). Additionally, we also identify specific intracellular
signaling molecules, which are involved in modulating
 
a
 
V
 
b
 
3
 
 to a prothrombin-competent binding state. More-
over, we show directly that 
 
a
 
V
 
b
 
3
 
 discriminates between
activation-dependent and activation-independent ligands,
and prothrombin serves as the prototype of an activation-
dependent ligand for 
 
a
 
V
 
b
 
3
 
 on vascular cells.
 
Materials and Methods
 
Reagents
 
Human prothrombin purchased from Alexis Corp. (San Diego, CA) and
Enzyme Research Corp. (South Bend, IN) was 
 
.
 
99% pure as assessed by
SDS-PAGE (Laemmli, 1970). The preparations used contained only one
major Coomassie blue staining band, and this protein reacted with mAb
to prothrombin (Biodesign International, Kennebunk, ME) in Western
blots. Humanized mAb c7E3 was from Centocor (Malvern, PA); 
 
a
 
V
 
b
 
3
 
-
specific mAb LM609 (Cheresh, 1987) was from Chemicon (Temecula,
CA). FITC-goat antiÐmouse IgG was purchased from Zymed Laborato-
ries (South San Francisco, CA); polyclonal affinity-purified antibodies
against prothrombin were from Haematologic Technologies Inc. (Essex
Junction, VT); BSA (fraction V, crystalline), calphostin C, bisindolylmale-
imide I and V, and calpeptin were purchased from Calbiochem-Nova-
biochem Corp. (La Jolla, CA). Calpain inhibitors I and II were from
Boehringer Mannheim (Mannheim, Germany). PMA, protease inhibi-
tors (leupeptin, pepstatin, PMSF), adenosine 5
 
9
 
-diphosphate sodium
salt (ADP) and cytochalasin B were from Sigma Chemical Co. (St.
Louis,  MO).
 
Purification of Proteins
 
Fibrinogen was purified from fresh human plasma by differential ethanol
precipitation (Plow et al., 1984). 
 
a
 
V
 
b
 
3
 
 was purified from detergent extracts
of human placental tissues by affinity chromatography using a KG-
GRGDSPÐSepharose column followed by elution with 20 mM EDTA as
described previously with minor modifications (Pytela et al., 1986; Smith
et al., 1990
 
b
 
). The preparations used exhibited only two major bands by
SDS-PAGE and protein staining with Coomassie Brilliant Blue, which
corresponded to the 
 
a
 
V
 
 and 
 
b
 
3
 
 subunits, and was judged as being 
 
.
 
95%
pure. When immobilized in wells, 
 
a
 
V
 
b
 
3
 
 preparation reacted with LM609,
an mAb specific for 
 
a
 
V
 
b
 
3
 
 (Cheresh, 1987), and did not react with CRC64,
an mAb specific for 
 
a
 
IIb
 
b
 
3
 
 (Mazurov et al., 1996), in an ELISA format.
 
Radioiodination
 
Na
 
125
 
I (specific activity 
 
5 
 
15Ð17 mCi 
 
125
 
I/mg of iodine) from Nycomed
Amersham Inc. (Princeton, NJ) was used for radioiodination. Prothrom-
bin was radiolabeled using a modified chloramine-T method (Plow et al.,
1984). The labeled prothrombin was indistinguishable from the unlabeled
form upon SDS-PAGE under reducing and nonreducing conditions.
When activated with Factor Xa 
 
1
 
 Va (5 mg/ml each; American Diagnos-
tica Inc., Greenwich, CT). all of the radiolabeled prothrombin could be
converted to thrombin within 30 min as assessed by gel analysis. Further-
more, the rate of activation of labeled and nonlabeled prothrombin by
Factor Xa or Factor Xa/Va was the same as assessed with the Spec-
trozyme (American Diagnostics, Inc.) thrombin substrate (Byzova and
Plow, 1997). Radioiodinated prothrombin was stored at 4
 
8
 
C and used
within 3Ð4 d of labeling.
 
Solid-Phase Ligand Binding Assays
 
The binding of prothrombin to immobilized 
 
a
 
V
 
b
 
3
 
 was performed as de-
scribed (Charo et al., 1991; Byzova and Plow, 1997) with minor modifica-
tions. 
 
a
 
V
 
b
 
3
 
 (280 
 
m
 
g/ml) was diluted 1:70 in a buffer containing 10 mM Tris,
150 mM NaCl, pH 7.4 (Buffer A), and immobilized onto 96-well microti-
ter plates (Costar Corp., Cambridge, MA) at 400 ng per well for overnight
at 4
 
8
 
C. The plates were then washed and post-coated with 40 mg/ml BSA
overnight at 48C or 1 h at 378C. The functional activity of the immobilized
aVb3 was assessed relative to 125I-fibrinogen binding to the same receptor
preparations (Suehiro et al., 1996). 125I-prothrombin was added in Buffer
A, containing 2 mg/ml BSA and the selected divalent cations. After incu-
bation for selected times (75Ð120 min) at 378C, wells were washed 4Ð5
times with Buffer A, and bound prothrombin was quantitated by counting
the bound radioactivity in a g-counter. In some experiments, aVb3-coated
wells were preincubated for 20 min with mAbs or peptides before addition
of 125I-prothrombin. When fibrinogen was used as a competitor, H-D-Phe-
Pro-Arg-chloromethylketone (Bachem, Torrance, CA) was included at a
final concentration of 30 mg/ml. Nonspecific binding was measured in the
presence of a 50-fold excess of unlabeled prothrombin. Data were deter-
mined as the means of triplicate or quadruplicate measurements at each
experimental point.
Cell Culture
Primary cultures of HUVEC, human aortic smooth muscle cells (HASMC),
and human aortic endothelial cells (HAEC) were provided by Drs. Paul
DiCorleto and Donald Jacobsen (Cleveland Clinic Foundation, OH).
HUVEC were grown to preconfluence in 162-cm2 plastic flasks (Costar
Corp.) in DME/F12 (BioWhittaker Inc., Walkersville, MD) supplemented
with 15% FBS (BioWhittaker Inc.), 150 mg/ml endothelial growth factor
(Clonetics Corporation, San Diego, CA), and 90 mg/ml heparin (Sigma
Chemical Co., St. Louis, MO; DÕSouza et al., 1996). The cells were used
within the second to fourth passage. HAEC were grown to preconfluence
in 162-cm2 plastic flasks (Corning Costar Corp.), coated with 0.1% gelatin
(Sigma Chemical Co.), in DME/F12 (BioWhittaker Inc.) supplemented
with 15% FBS (BioWhittaker Inc.), 150 mg/ml endothelial growth factor
(Clonetics), and 90 mg/ml heparin (Sigma Chemical Co.) and used within
the third to fifth passage. HASMC were grown in 162-cm2 plastic flasks
(Costar Corp.) in DME Medium/F12 (GIBCO BRL, Gaithersburg,
MD)  supplemented with 10% FBS (GIBCO BRL), 75 mg/ml endothelial
growth factor (Clonetics), and 45 mg/ml heparin (Sigma Chemical Co.),
and used within the fourth to seventh passage. aVb3 expression was veri-
fied by flow cytometry (as described below) and only aVb3-positive cul-
tures were used in adhesion assays. aVb3-negative cultures did not demon-
strate an agonist-induced increase in adhesion to prothrombin.Byzova and Plow Activated aVb3 Recognition of Prothrombin 2083
HUVEC, HAEC, and HASMC Adhesion Assays
HUVEC and HAEC were washed three times with PBS and harvested by
gentle trypsinization (0.25 mg/ml trypsin, 0.01% EDTA solution; Clonet-
ics). Cells were collected into a tube containing trypsin neutralizing solu-
tion (Clonetics) and immediately centrifuged at 500 g for 10 min. The cells
were resuspended in 107 cells/ml in DME/F12, containing 1% BSA (adhe-
sion buffer). Calcein AM (50 mg; Molecular Probes, Eugene, OR) was sol-
ubilized in 10 ml of DMSO (Sigma Chemical Co.), and then diluted with
500 ml PBS. This Calcein solution (200 ml) was added to 2 ml of cell sus-
pension at 5 3 106 cells/ml. 24-well plates (Costar Corp.) were precoated
with prothrombin for 1 h at 378C (10 mg/well in 50 mM NaHCO3, 150 mM
NaCl, pH 8.0) or fibrinogen (10 mg/well) and postcoated with 3% BSA for
1 h at 378C. Cells were labeled by Calcein AM for 30 min as described
above and diluted to 5 3 105 cells/ml in DME/F12, containing 1% BSA.
For HASMC, all procedures were the same but the trypsin solution was
from BioWhittaker Inc. Cells were preincubated with or without inhibi-
tors, light-activated calphostin C (final concentration, 1 mM), bisindolyl-
maleimide I and V (20 nM each), calpeptin (50 mg/ml), the combination of
calpain inhibitors I and II (100 mg/ml, each) in the presence of additional
1 mM CaCl2 or 1 mM MnCl2, and then stimulated with PMA (200 nM) or
various concentrations of ADP. The cell suspension (0.3 ml) was added to
the coated wells. In some experiments, PMA-stimulated cells were treated
by cytochalasin B (final concentrations, 0.1, 1, or 10 mM). At selected times
(50Ð70 min at 378C), wells were gently washed three times with DME/F12.
Adherent cells were quantitated in a Fluorescence Multi-Well Plate
Reader (PerSeptive Biosystems, Framingham, MA) and examined micro-
scopically.
Flow Cytometry
HUVEC, HAEC, or HASMC, harvested as described above, were sus-
pended at 8 3 105/ml in adhesion buffer and incubated with LM609 (10
mg/ml) or with control mouse IgG for 60 min at 378C. The cells were
washed by centrifugation in DME/F12 1 1% BSA, incubated with FITC-
goat antiÐmouse IgG on ice for 20 min, and then analyzed by flow cytome-
try. Flow cytometry was performed using a FACScan¨ instrument; 10,000
events were recorded; and the data were analyzed using the CellQuest
software program (version 1.2).
Binding of 125I-Prothrombin to HUVEC in Suspension
HUVEC were diluted to 7 3 105/ml in DME/F12, with or without 0.5 mM
MnCl2. The cells were preincubated with mAb LM609 (20 mg/ml), nonim-
mune immunoglobulins (20 mg/ml), c7E3 (20 mg/ml), or fibrinogen (100
and 500 mg/ml) for 5 min, and 125I-prothrombin was then added at selected
concentrations. Cells were activated with PMA at 200 nM as specified. Af-
ter 75 min at 378C, cell-bound ligand was separated by centrifugation
through 20% sucrose for 2.5 min at 228C in Beckman microfuge, and the
cell-bound radioactivity was measured in a gamma-counter. Data were de-
termined with quadruplicate measurements at each experimental point.
Binding of 125I-Prothrombin to the HUVEC Monolayer
HUVEC were suspended at 1 3 106/ml in DME/F12, containing 1% BSA
and seeded into 24-well plates, precoated by 0.1% gelatin. After 4 h incu-
bation, nonadherent cells were removed, and the media was changed to
supplemented DME/F12 for overnight. 7 h before the experiment, the me-
dia was changed for DME/F12 containing 1% BSA and no serum. Cells
were preincubated with c7E3 (30 mg/ml) or GRGDSP peptide (100 mM)
or without inhibitors for 10 min and then treated by PMA at 200 nM or
0.5 mM MnCl2 as indicated. 125I-prothrombin was then added at concen-
tration of 50 mg/ml. After 70 min at 378C, wells were washed three times
by PBS, and bound radioactivation solubilized in 0.3 ml 1 N NaOH, and
measured in a g-counter. Quadruplicate measurements were made at each
experimental point.
Results
125I-Prothrombin Binding to Purified aVb3
As an initial analysis, we sought to determine whether pu-
rified aVb3 could bind prothrombin. The aVb3 used was
isolated from human placenta by affinity chromatography
on a RGD column and contained no detected aIIbb3, as as-
sessed immunochemically. The functional activity of the
isolated aVb3 was evaluated with the receptor immobilized
onto microtiter plates and using fibrinogen as a well-char-
acterized  aVb3 ligand (e.g., Smith and Cheresh, 1990;
Smith et al., 1990a). The binding of fibrinogen was sup-
ported by Mn21 and was inhibited by Ca21, consistent with
the data of Smith et al. (1994); and this interaction was
completely inhibited by RGD-containing peptides and the
aVb3-specific mAb, LM609.
With evidence of receptor purity and function, the bind-
ing of prothrombin to aVb3 was assessed. Increasing
concentrations of 125I-prothrombin were added to wells
coated with aVb3. As shown in Fig. 1 A, prothrombin
bound in concentration-dependent manner, and this inter-
action was inhibited by 50-fold excess of nonlabeled
ligand. The concentration of 125I-prothrombin required for
half-maximal binding was ,25 mg/ml. At saturation, 13.6 3
1010 prothrombin molecules bound to the aVb3-coated
wells (see Fig. 1 A). In the presence of 1 mM MnCl2,
z8.4 3 1010 fibrinogen molecules were maximally bound.
Thus, the stoichiometry of binding of the two ligands to
the receptor was similar. The specificity of prothrombin
binding to aVb3 is documented in Fig. 1 B. Typical of the
binding of adhesive ligands to aVb3, the interaction of pro-
thrombin with the receptor was cation dependent: Ca21
and Mn21 supported binding, and EDTA inhibited the in-
teraction. Two different mAbs reactive with aVb3, LM609
and c7E3, also inhibited prothrombin binding to the re-
ceptor (Fig. 1 B) whereas nonimmune IgG had no effect.
Although both mAbs were effective inhibitors of 125I-pro-
thrombin binding to aVb3, c7E3, even at higher concentra-
tions, tended to be slightly less inhibitory than LM609,
which may reflect the difference in the specificity of these
mAbs (Cheresh, 1987; Jordan et al., 1997). The RGD-
containing peptide, GRGDSP, produced dose dependent
inhibition and, at a high concentration of 100 mM, was as
effective as the mAbs and EDTA in inhibiting the interac-
tion. Taken together, this inhibitory profile demonstrates
that prothrombin can bind to aVb3 via a RGD recognition
specificity, which typifies the recognition of adhesive
ligands by this integrin.
aVb3-dependent Adhesion of Activated Vascular Cells 
to Prothrombin
In view of recent evidence indicating that prothrombin is
deposited in the vessel wall (McBane et al., 1997), we next
sought to determine whether prothrombin could function
as an adhesive ligand for aVb3 in intact cells. The results of
these analyses are shown microscopically in Fig. 2 and
quantitatively in Fig. 3. Under conditions where pro-
thrombin supported nonstimulated platelet adhesion, we
found that nonstimulated HUVEC did not adhere to im-
mobilized prothrombin (Figs. 2 A and 3 A). In contrast,
adhesion of PMA-stimulated cells was evident within 30
min, and after 50Ð60 min, many of the adherent cells were
spread on the prothrombin substratum (Fig. 2 B). With 2 3
105 HUVEC added to the prothrombin coated wells, the
percentage of adherent cells ranged from 30 to 60% of the
added cells; of the adherent cells, z30Ð40% were spread
within 1 h (Fig. 2 B), and this percentage increased withThe Journal of Cell Biology, Volume 143, 1998 2084
longer incubation. Background cell adhesion to microtiter
wells coated with BSA was not significantly affected by
PMA stimulation, and the aVb3 mAbs (LM609 and c7E3)
and GRGDSP had no effect on the nonspecific adhesion
of stimulated or nonstimulated cells to BSA (not shown).
Verifying the role of aVb3 in the adhesion of the PMA-
stimulated HUVEC to prothrombin, mAbs LM609 and
c7E3 completely blocked adhesion, as did GRGDSP (100
mM; Fig. 3 A). In contrast, neither nonimmune IgG nor a
control peptide significantly affected HUVEC adhesion
(Fig. 3 A). As an additional indication of specificity, anti-
bodies to prothrombin also blocked adhesion to the immo-
bilized substrate by .80% (Fig. 3 A, calculated by assign-
ing the adhesion in the absence of PMA a value of 0%).
This set of data demonstrates that PMA-activated HU-
VEC, but not resting cells, are capable of interacting with
immobilized prothrombin via aVb3 in a RGD-dependent
manner.
In the presence of Mn21, a cation that stimulates the
ligand binding function of aVb3 (Smith et al., 1994), as well
as many other integrins, (Mould et al., 1995; Suehiro et al.,
1997), adhesion of the cells to prothrombin was observed
without the requirement of an additional stimulus (Figs. 2
C and 3 B). This adhesion also was completely inhibited by
GRGDSP, LM609, and c7E3, supporting the essential role
for aVb3 in the interaction (Figs. 2 D and 3 B). No additive
effect on HUVEC adhesion was observed when PMA and
Mn21 were used together (not shown); however, we did
find that after 6Ð7 passages, HUVEC required both PMA
and Mn21 to adhere to prothrombin. In Fig. 3 C, evidence
is provided that adhesion to prothrombin also is observed
with endothelial cells of a different origin. HAEC adhered
to prothrombin in a similar manner as HUVEC, i.e., ad-
hesion was stimulated by PMA and inhibited by LM609.
Furthermore, as shown in Fig. 3 C, soluble prothrombin
inhibited adhesion to the immobilized ligand. The later
observation suggests that the soluble form of prothrombin
is recognized by aVb3, and surface denaturation is not re-
quired for prothrombin to become a ligand for the recep-
tor. This interpretation is supported by subsequent bind-
ing studies using soluble prothrombin as a ligand for aVb3
(see below).
The capacity of prothrombin to support cell adhesion
was not restricted to endothelial cells. Upon PMA stimula-
tion, the adherence of a second type of vascular cell,
HASMC, to prothrombin increased dramatically. The in-
creased adhesion induced by PMA was 80% (calculated
by assigning the adhesion in the absence of PMA a value
of 0%) inhibited by mAb LM609 (Fig. 4) but not by non-
immune Ig. We also found that Mn21 supported aVb3-
mediated adhesion of HASMC to prothrombin (not shown).
Furthermore, with HASMC, a physiologically relevant ag-
Figure 1. 125I-prothrombin bind-
ing to purified aVb3. (A) Satura-
tion isotherms of 125I-prothrombin
binding (150 min at 378C) to puri-
fied and immobilized aVb3. Spe-
cific binding (j) was derived by
subtracting the nonspecific binding
(s), the residual binding in the
presence of a 50-fold excess of
nonlabeled prothrombin, from the
total binding (d), no inhibitor
present. Data are derived in the
presence of 1 mM Ca21. (B)  125I-
prothrombin binding to immobi-
lized  aVb3 in the presence of 1 mM
Ca21 ( black bars), 1 mM Mn21
(gray bar), and 10 mM EDTA
(open bar). Wells were preincubated with mAb c7E3 or LM609 (20 mg/ml each); or GRGDSP (100 mM and 100 mM) and 125I-prothrom-
bin was added at a concentration of 30 mg/ml. The total binding (not corrected for nonspecific background) of prothrombin to aVb3 in
the presence of 1 mM Ca21 without inhibitors was assigned a value of 100%. The data shown are means and SD of triplicates in one ex-
periment and are representative of three separate experiments.
Figure 2. Photomicrographs of HUVEC adherent to immobi-
lized prothrombin in the absence (A) and presence of 200 nM
PMA (B) or in the presence of 1 mM MnCl2 (C). In D, cells were
pretreated by mAb LM609 (20 mg/ml) to aVb3 and then stimu-
lated with PMA. Bar, 50 mm.Byzova and Plow Activated aVb3 Recognition of Prothrombin 2085
onist (Boarder and Hourani, 1998; Murthy and Makhlouf,
1998), ADP, was shown to induce adhesion to prothrom-
bin. ADP increased adhesion in a dose-dependent man-
ner; and, at higher concentrations (200Ð2,000 mM), ad-
hesion was as extensive as that induced by PMA. The
adhesion induced by ADP was aVb3-mediated as LM609
was an effective inhibitor. We also observed that ADP in-
duced adhesion of HUVEC to prothrombin (not shown)
although higher concentrations of the agonist were re-
quired to obtain a comparable effect. Taken together,
these data indicate that prothrombin serves as an adhesive
ligand for aVb3 on HUVEC, HAEC, and HASMC.
Binding of Prothrombin to Endothelial Cells
We next sought to assess whether aVb3 on vascular cells is
capable of recognizing not only immobilized but also solu-
ble prothrombin and how cellular activation might influ-
ence this interaction. 125I-prothrombin was incubated with
HUVEC in a single cell suspension in the presence of Ca21
and Mg21 (DME/F12 without additional cations) or in the
presence of additional 1 mM Mn21. Results of a typical ex-
periment are shown in Fig. 5 A, which illustrates the influ-
ence of increasing concentrations of added 125I-prothrom-
bin on specific prothrombin binding to HUVEC under the
two divalent cation conditions. The nonspecific binding
was determined in the presence of 50-fold molar excess of
unlabeled prothrombin and corresponded to 10Ð15% of
the total binding at the concentrations of 125I-prothrombin
added. From the data presented in Fig. 5 A, it is evident
that the addition of Mn21 cause a dramatic increase of 125I-
prothrombin binding to HUVEC. Saturation of binding
was apparent in the presence of Mn21 at prothrombin con-
centrations above 50 mg/ml, which corresponds to half the
prothrombin concentration in plasma. At this saturating
concentration, 958,000 6 108,500 prothrombin molecules
bound per cell in the presence of Mn21, compared with
18,600 6 2,050 molecules per cell in the presence of Ca21.
Thus, although Ca21 did support limited specific binding
of prothrombin to aVb3 (inhibitable by nonlabeled pro-
thrombin, c7E3 and LM609), Mn21 enhanced this interac-
tion by z50-fold.
To investigate whether 125I-prothrombin binding in the
presence of Mn21 was attributable to aVb3, binding studies
were performed in the presence of mAbs LM609 and c7E3
and GRGDSP. As shown in Fig. 5 B, LM609 inhibited 125I-
prothrombin binding to HUVEC by 75Ð80% and to c7E3
by z50%. At the same concentration, nonimmune IgG
had no effect. The extent of inhibition by GRGDSP was
similar to that produced by c7E3. The stimulatory effect of
Mn21 and the inhibition profile of 125I-prothrombin bind-
Figure 3. Endothelial cell adhesion to prothrombin requires stimulation. HUVEC (A and B) or HAEC were harvested, labeled by
Calcein, and diluted to the 5 3 105 cells per ml in DME containing 0.2% BSA and 1 mM CaCl2. In A and B, HUVEC were stimulated
with 200 nM PMA or 1 mM Mn21, respectively. Inhibitors used were: mAb LM609 or mAb c7E3 (20 mg/ml each), GRGDSP peptide
(100 mg), or polyclonal antibodies to prothrombin (anti-prothrombin). In C, HAEC were stimulated with PMA. In addition to the inhib-
itors used in A and B, soluble prothrombin was used at a concentration of 300 mg/ml. After 50 min, adhesion was measured. Adhesion in
the presence of 1 mM CaCl2 and 1 PMA (A and C) or in the presence of 1 mM MnCl2 (B) and in the absence of inhibitors was assigned
a value of 100%. The data shown are means and SD of quadruplicates in one experiment and are representative of seven separate ex-
periments.
Figure 4. PMA-stimulated adhesion of HASMC to prothrombin
is aVb3 dependent. HASMC were harvested, labeled by Calcein,
diluted to the 5 3 105 cells per ml in DME containing 1% BSA
and 1 mM CaCl2. HASMC were stimulated with either 200 nM
PMA (black bars) or ADP (striped bars) at the indicated concen-
trations. mAb LM609 at a concentration of 20 mg/ml was in-
cluded as indicated. After 40 min, adhesion was measured. Adhe-
sion in the presence of PMA without inhibitors present was
assigned a value of 100%. Nonspecific adhesion to BSA-coated
wells was subtracted. The data shown are means and SD from
three experiments.The Journal of Cell Biology, Volume 143, 1998 2086
ing confirm the role of aVb3 in interaction of HUVEC with
soluble prothrombin.
Next, we assessed whether 125I-prothrombin is capable
of interacting with HUVEC in a monolayer. 125I-pro-
thrombin at 50 mg/ml was added to a confluent and intact
HUVEC monolayer in the presence of PMA, 0.5 mM
Mn21 or no addition. After 70 min, the cells were rapidly
washed and HUVEC-associated radioactivity was ex-
tracted and counted. The aVb3-mediated component of
prothrombin binding accounted for 194,000 6 5,780 mole-
cules/cell. A contribution of aVb3 to prothrombin binding
also was demonstrable in the presence of 0.5 mM Mn21
(Fig. 6). It should be noted that substantial specific binding
of  125I-prothrombin (inhibited by excess nonlabeled pro-
thrombin) to the untreated HUVEC monolayer was ob-
served (not shown), but this interaction was unaffected
by mAb LM609, i.e., the binding was not aVb3-mediated.
PMA-stimulation substantially increased the 125I-prothrom-
bin binding, and this increment was abrogated by LM609
as well as c7E3 (Fig. 6). Thus, aVb3 can recognize pro-
thrombin, either as an adhesive substrate or as a soluble
ligand, provided the HUVEC had been exposed to PMA
or Mn21. To determine whether 125I-prothrombin binding
to the HUVEC monolayer resulted in internalization of
ligand, we tested whether EDTA could elute bound pro-
thrombin from the cells. 125I-prothrombin was bound to
the cells for 70 min and then HUVEC were washed 4Ð5
times with phosphate buffer, containing 10 mM EDTA.
This treatment did not disrupt the monolayer as assessed
microscopically, but did elute 96% of the bound 125I-pro-
thrombin, indicating that the reaction was reversible and
that prothrombin was not internalized under the condi-
tions used.
Competition between Prothrombin and Fibrinogen
for aVb3
The capacity of a major aVb3 ligand, fibrinogen, to com-
pete with prothrombin for binding to the receptor was as-
sessed. These analyses were conducted with both purified
aVb3 and with HUVEC in suspension, and the experi-
ments were performed under different divalent cation
conditions. The results are summarized in Table I. Previ-
ous studies have established that fibrinogen binds poorly
to purified aVb3 in the presence of Ca21 (Smith et al., 1994;
Suehiro et al., 1996), and fibrinogen, even in concentra-
tions as high as 500 mg/ml, was a poor inhibitor of pro-
thrombin binding, producing only 11% inhibition in 1 mM
Ca21. In the presence of Mn21, fibrinogen was a more ef-
fective inhibitor, producing 40% inhibition at 500 mg/ml.
Nevertheless, substantial binding of prothrombin was still
observed. The data obtained for 125I-prothrombin binding
to HUVEC were consistent with those obtained in the pu-
Figure 5. HUVEC bind soluble 125I-prothrom-
bin. (A) HUVEC in suspension were incubated
with increasing concentrations of 125I-prothrom-
bin in DME/F12 in the presence of 0.5 mM
MnCl2 or 1 mM CaCl2 for 60 min, and cell-bound
radioactivity was quantitated as described. Non-
specific binding was measured in the presence of
50-fold excess of nonlabeled prothrombin and
subtracted to yield the specific binding data
shown. Values represent the means and SD of
four determinations. (B) Specificity of prothrom-
bin binding to HUVEC. 125I-prothrombin (50
mg/ml) was incubated with HUVEC (8 3 105
cells/ml) in the presence of mAb LM609, mAb
c7E3 (20 mg/ml each; a similar concentration of
nonimmune IgG was without effect), or 100 mM
GRGDSP. MnCl2 (1 mM) was added to the
DME/F12 media, and cell-bound radioactivity was measured after 60 min incubation. Nonspecific binding was measured in the presence
of 50-fold excess of nonlabeled prothrombin and subtracted. The data shown are means and SD of quadruplicates in one experiment
and are representative of three separate experiments.
Figure 6. 125I-prothrombin binding to a HUVEC monolayer.
Confluent cell monolayers were incubated with 50 mg/ml 125I-pro-
thrombin in DME/F12-1% BSA in the presence or absence of
200 nM PMA (solid bars) or 0.5 mM MnCl2 (gray bars). Cells
were preincubated with c7E3 (30 mg/ml) or a cyclic RGD peptide
(10 mM) or without inhibitors for 10 min. After 70 min at 378C,
wells were washed three times with PBS, and the cells were solu-
bilized in 1 N NaOH. Prothrombin binding to nonstimulated en-
dothelial cells was subtracted from the total binding, and the dif-
ference is displayed. Values are means and SD of quadruplicates
from one of five experiments with similar results.Byzova and Plow Activated aVb3 Recognition of Prothrombin 2087
rified system. Specifically, in the absence of Mn21, fibrino-
gen was a poor inhibitor of 125I-prothrombin binding. Inhi-
bition was more extensive in the presence of 1 mM Mn21,
but substantial prothrombin binding was still observed,
even at the higher fibrinogen concentration. Thus, under
some, but not all conditions, fibrinogen competes but does
not appear to be a particularly effective inhibitor of 125I-pro-
thrombin binding to aVb3.
Molecular Basis for Adhesion of Activated Vascular 
Cells to Prothrombin
We sought to understand the mechanism by which aVb3
became competent to bind prothrombin in the presence of
agonist. FACS¨ analysis was used to determine whether
the expression levels of aVb3 on HUVEC and HASMC is
altered by PMA stimulation. This analysis confirmed high
expression of aVb3 on HUVEC and lower expression on
HASMC. PMA-stimulated cells were found to express
aVb3 at levels similar to that found on nontreated cells.
These data indicate that short-term PMA treatment did
not alter the expression level of aVb3.
Since PMA is a potent activator of protein kinase C
(PKC), the possible role of PKC in PMA-stimulated HU-
VEC adhesion on prothrombin was examined. Calphostin
C, a specific and potent inhibitor of PKC (Kobayashi et al.,
1989), completely blocked the effect of PMA on HUVEC
adhesion to prothrombin (see Fig. 8 A). Similar results
were obtained with a second PKC inhibitor, bisindolyl-
maleimide I, but not with the low affinity control inhibitor,
bisindolylmaleimide V (Toullec et al., 1991). At the con-
centration used, calphostin C and bisindolylmaleimide I
did not affect cell viability, as assessed by trypan blue
staining, even with extended incubation times. These re-
sults indicate that the effect of PMA on increased adhe-
sion depends upon PKC. Of note, treatment with calphos-
tin C also abolished attachment and spreading of HUVEC
on prothrombin in the presence of Mn21 (see Fig. 8 A).
This observation suggests that, like PMA, the induction of
prothrombin binding to aVb3 on HUVEC by Mn21 re-
quires inside-out signaling events.
As a next step, we investigated the role of another po-
tential candidate in PMA-induced cell adhesion to pro-
thrombin, calpain. Numerous activities have been ascribed
to this neutral calcium-dependent protease, including the
capacity to cleave the cytoplasmic tail of b3 subunit (Du et al.,
1995) and to regulate cell migration (Huttenlocher et al.,
1997). HUVEC, pretreated with membrane permeable
calpain inhibitor, calpeptin (Tsujinaka et al., 1988), were
unable to adhere to prothrombin either after PMA stimu-
lation or in the presence of Mn21 (Fig. 7 A). The combina-
tion of calpain inhibitors I and II also was effective in in-
hibiting HUVEC adhesion to prothrombin. These findings
indicate that active calpain is required for modulation of
aVb3 affinity on endothelial cells induced by PMA and
Mn21. To determine if PMA stimulation exerted its effect
on prothrombin binding by aVb3 by influencing post-
ligand binding events, such as integrin clustering and cell
spreading, PMA-activated cells were treated with cytocha-
lasin B, an effective inhibitor of actin cytoskeleton reorga-
nization. Untreated HUVEC adhered and spread on pro-
thrombin, whereas, in the presence of cytochalasin B, the
cells remained adherent but entirely rounded (Fig. 8 B).
This effect indicates that the cytochalasin treatment al-
tered the cytoskeletal response of the cells. Quantitation
of the number of adherent cells verified that the adhesion
of PMA-stimulated HUVEC to prothrombin was not sub-
stantially changed by cytochalasin B at a concentration of
1 or 10 mM (Fig. 8 C). Neither of these concentrations
were toxic for cells. HUVEC adhesion in the presence of
Figure 7. Short-term PMA treatment does not increase aVb3 ex-
pression. HUVEC (A and B) or HASMC (C and D) were grown
and harvested as described. For each experimental point, 106
cells were incubated in the presence of nonimmune IgG (1) or
mAb LM609 (2) for 50 min. In B and D cells were treated by 200
nM PMA. After washing, the cells were incubated with anti-
mouse IgG FITC-conjugated antibody and analyzed by flow cy-
tometry.
Table I. Effect of Fibrinogen on Prothrombin Binding to aVb3 
in a Purified System and on Endothelial Cells
Cation
conditions
125I-Prothrombin binding
to purified aVb3*
125I-Prothrombin binding
to HUVECà
1 mM Ca21 1 mM Mn21
2 mM Ca21
2 mM Mg21
1 mM Ca21
2 mM Mg21
1 mM Mn21
No competitor 100 6 7.1% 100 6 9% 100 6 12% 100 6 18%
Fibrinogen 89 6 9% 60.7 6 4% 85.4 6 11% 38 6 5%
(500 mg/ml)
Fibrinogen 107 6 14% 93 6 10.3% 92.7 6 11.9% 76.9 6 4%
(100 mg/ml)
In all assays, H-D-Phe-Pro-Arg-chloromethylketone was present throughout at a final
concentration of 30 mg/ml. Specific prothrombin binding, inhibited by excess nonla-
beled prothrombin, was assigned the value of 100% under each cation condition. With
purified and immobilized aVb3, 100% was 7.7 3 1010 molecules/well in the presence
of 1 mM Ca21 and 9.8 3 1010 molecules/well in Mn21. In the cell experiments, 100%
was 110,000 molecules/cell in the presence of 2 mM Ca21, 2 mM Mg21, and 780,000
molecules/cell in the presence of 1 mM Ca21, 2 mM Mg21, and 1 mM Mn21. Values
are the means 6 SD of quadruplicates in one experiment which is representative of at
least five experiments.
*Experimental conditions are the same as in Fig. 1 with purified aVb3 immobilized
onto microtiter wells.
àExperimental conditions are the same as in Fig. 5 with HUVEC in suspension.The Journal of Cell Biology, Volume 143, 1998 2088
Mn21 or Mn211 PMA also was unaffected by cytochalasin
B. These results suggest that PMA stimulation modulates
the affinity of aVb3 for the prothrombin ligand and that cy-
toskeletal reorganization is not required for recognition of
prothrombin by the receptor. Of note, we found that cer-
tain concentrations of cytochalasin B stimulated cell adhe-
sion to prothrombin in the absence of PMA or Mn21. Sim-
ilar observations were reported by Qi et al. (1998), who
found that cytochalasin D could activate aIIbb3-mediated
adhesion to fibrinogen.
To determine if the activation requirement for recogni-
tion of prothrombin by aVb3 extends to other aVb3 ligands,
we assessed the effects of cell stimulation and of the inhib-
itors, calphostin C and calpeptin, on aVb3-mediated HU-
VEC adhesion to fibrinogen. Consistent with previous re-
ports (Cheresh, 1987; DÕSouza et al., 1996; Suehiro et al.,
1997), HUVEC adhere well to fibrinogen although only a
portion of this adhesion was aVb3 mediated. aVb3-depen-
dent adhesion was identified as that component of total
cell adhesion that was sensitive to the anti-aVb3 blocking
mAbs, LM609 or c7E3 (Fig. 9 A). For nonstimulated cells,
aVb3-mediated adhesion was z37% (100% is defined as
the total adhesion in the presence of PMA). Treatment
with PMA caused an increase in total HUVEC adhesion,
but the aVb3-mediated portion of adhesion remained un-
changed (35%). The same pattern was demonstrable in
the presence of Mn21. In the experiment shown in Fig. 9 B,
aVb3-mediated adhesion in the presence of Mn21 was 17%
of the total adhesion, and with Mn21 1 PMA present, 19%
of the total adhesion was aVb3 mediated (Fig. 9 B). In con-
trast to HUVEC adhesion to prothrombin, pretreatment
of HUVEC with calphostin C did not significantly de-
creased the number of cells adherent to fibrinogen (Fig. 9
C). Furthermore, whereas pretreatment of HUVEC with
calpeptin resulted in complete inhibition of cell adhesion
to prothrombin, calpeptin had no effect on cell adhesion to
fibrinogen (Fig. 9 D). Thus, the requirements for aVb3-
mediated adhesion to prothrombin and fibrinogen are
quite distinct.
Discussion
In this study, we sought to assess whether prothrombin is a
ligand for aVb3 on vascular cells. A direct interaction be-
tween prothrombin and aVb3 on human vascular cells, en-
dothelial cells, derived from umbilical vein and from aorta,
and smooth muscle cells was demonstrable, establishing a
previously unrecognized interface between the adhesive
and procoagulant properties of these cells. Moreover, in
characterizing this interaction, we found that activation of
aVb3 by model agonists (PMA or Mn21) or physiological
agonists (ADP) is required for recognition of prothrom-
bin, and this requirement is not necessary for fibrinogen to
engage the receptor. Therefore, whereas recent studies
have emphasized that aVb3 can exist in different activation
states (Pelletier et al., 1996; Bennett et al., 1997; Sadhu et
al., 1998), it appears that the functionality of the receptor
is defined by the ligand under analysis; and prothrombin
and fibrinogen serve as prototypes of activation-depen-
dent and activation-independent ligands for aVb3 on vas-
Figure 8. Effects of protein kinase C and calpain inhibitors (A)
and cytochalasin B (B and C) on adhesion of PMA- and MnCl2-
treated HUVEC to immobilized prothrombin. HUVEC adhesion
was measured (see legend to Fig. 3 and Materials and Methods)
in the absence (open bar) or presence of 200 nM PMA (black
bars) or in the presence of 0.5 mM MnCl2 (gray bars). In A, cells
were pretreated with calpeptin (50 mg/ml), calpain inhibitor I and
II (100 mg/ml each), bisindolylmaleimide V (BIM V) and bisin-
dolylmaleimide I (BIM I; 20 nM each) or calphostin C light-acti-
vated; 1 mM). In B, adherent cells in the absence or presence (0.1
mm) of cytochalasin B were photographed at 403. Bar, 50 mm. In
C, adhesion of stimulated cells was measured after 50 min in the
absence or presence of cytochalasin B. Adhesion in the presence
of 200 nM PMA without inhibitors was assigned a value of 100%.
The data shown are means and SD from three experiments.Byzova and Plow Activated aVb3 Recognition of Prothrombin 2089
cular cells. Furthermore, our results implicate the PKC
pathway and calpain activity in controlling the activation
state of aVb3 on endothelial and smooth muscle cells.
Three approaches were used to characterize the interac-
tion of prothrombin with aVb3. First, the binding of pro-
thrombin to the purified receptor was analyzed. Specific
and saturable binding of prothrombin to purified and im-
mobilized aVb3 was demonstratable. This interaction was
cation-dependent and was mediated by a RGD recogni-
tion specificity as RGD-containing peptides blocked bind-
ing. These are characteristics of the interaction of aVb3
with many of its adhesive ligands (e.g., Felding-Haber-
mann and Cheresh, 1993). Second, the capacity of immobi-
lized prothrombin to support aVb3-dependent adhesion
was measured. Prothrombin was found to support attach-
ment and spreading of stimulated HUVEC, HAEC and
HASMC. This adhesion was mediated by aVb3 as evi-
denced by its blockade by mAbs to the receptor and by
RGD-containing peptides. As an additional specificity
control, antibodies to prothrombin also blocked this adhe-
sion. Third, the ability of aVb3 on cells to bind soluble pro-
thrombin was evaluated. aVb3 mediated the binding of
prothrombin to stimulated HUVEC in suspension and in a
monolayer, and this interaction required stimulation of the
cells. Taken together, these analyses clearly document that
prothrombin, presented either in a soluble or an immobi-
lized form, is a ligand for aVb3 on vascular cells.
Prothrombin contains a RGD sequence within its cata-
lytic domain. Analysis of the crystal structure of thrombin
revealed that the RGD is involved in the formation of the
active site and lies at the bottom of the S1 specificity
pocket (Stubbs and Bode, 1993). This positioning is likely
to preclude access of aVb3 and other integrins with a RGD
recognition specificity to the sequence in native thrombin.
The orientation of the RGD may be different in pro-
thrombin and permit recognition by aVb3. In the crystal
structure of prethrombin 2 (Vijayalakshmi et al., 1994), a
catalytically inactive intermediate generated during pro-
thrombin activation, the RGD sequence resides in a sur-
face-exposed configuration. As additional support for this
possibility, Bar-Shavit et al. (1991, 1993) demonstrated
that active thrombin was not adhesive but could be modi-
fied into a potent RGD-dependent adhesion molecule for
endothelial cells. Our data showing that soluble prothrom-
bin inhibits adhesion to the immobilized ligand suggest
that the requisite sequence(s) for aVb3 recognition are ex-
pressed on the surface of the native molecule. This inter-
pretation by no means excludes the possibility that other
sequences in prothrombin could mediate recognition of
prothrombin by aVb3; i.e., similar to the recognition of the
g chain, rather than the RGD sequence of fibrinogen by
aIIbb3 (Farrell et al., 1992), even though aIIbb3 also has a
RGD recognition specificity. Also to be resolved is whether
factor X, which also contains a RGD sequence, can inter-
act with aVb3.
The aVb3 integrin is widely expressed on vascular cells.
It is present on luminal and basolateral surfaces of endo-
thelial cells, on smooth muscle cells, and is also expressed
on certain circulating blood cells (Cheresh, 1987; Savill et
al., 1990; Moulder et al., 1991; Conforti et al., 1992; Brown et
al., 1994). This expression profile suggests that aVb3 is di-
rectly exposed to plasma proteins, including prothrombin.
From our analyses of the interaction of prothrombin with
aVb3, either in purified form or on cells, half-maximal
binding occurred at input concentrations of z50  mg/ml
and almost 106 prothrombin molecules were bound per en-
dothelial cell. Thus, the plasma concentration of pro-
thrombin at z100 mg/ml would potentially place substan-
tial quantities of prothrombin on cell surfaces that must be
nonthrombogenic to maintain hemostasis. In addition to
its presentation as a soluble ligand from plasma, pro-
thrombin also may be a relevant substrate for vascular cell
adhesion. Recent studies have demonstrated that pro-
thrombin is synthesized by smooth muscle cells (McBane
et al., 1997). Furthermore, prothrombin accumulates
within the vascular matrix, particularly at sites of lesion
formation. High levels of prothrombin have been identi-
fied in the aortic intima after deendothelializing injury
(Hatton et al., 1995) and in early atherosclerotic lesion
(Smith and Staples, 1981). Based on our studies of pro-
thrombin binding to aIIbb3, a potential functional conse-
quence of prothrombin binding to aVb3 would be its more
efficient activation to thrombin (Byzova and Plow, 1997).
Also, with the deposition of prothrombin in the vessel wall
under pathophysiological conditions (Hatton et al., 1995;
Smith and Staples, 1981), adhesion itself may be a biologi-
Figure 9. HUVEC adhesion to immobilized fibrinogen. HUVEC
were harvested, labeled by Calcein, diluted to the 5 3 105 cells
per ml in DME containing 1% BSA and 1 mM CaCl2 (A) or 1 mM
MnCl2 ( B). Specific aVb3-antagonists, mAb LM609, or mAb
c7E3 (20 mg/ml each), were included as indicated. In C, the cells
were pretreated with calphostin C at final concentration of 1 mM
or calpeptin (50 mg/ml). In D, HUVEC were treated with 200 nM
PMA (solid bars), and, after 50Ð60 min, adhesion was measured.
Adhesion in the presence of 1 mM CaCl2 1 200 nM PMA was as-
signed a value of 100%. The data shown are means and SD of
triplicates in one experiment and are representative of four sepa-
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cally relevant endpoint of prothrombinÐaVb3 interactions.
With these potential biological ramifications, the interac-
tion of prothrombin with this receptor requires tight regu-
lation. Such regulation appears to be established by the ac-
tivation state of aVb3. Whether competition with other
aVb3 ligands provides an additional level of control re-
mains to be established. In this regard, based upon their
plasma levels, the two primary competitors for plasma
prothrombin binding to aVb3 are predicted to be vitronec-
tin and fibrinogen. Denaturation is required for vitronec-
tin to become a soluble ligand for aVb3 (Seiffert and
Smith, 1997); with fibrinogen, the role of aVb3 in mediat-
ing its binding to HUVEC has been variable (Languino et
al., 1993). In our analyses, we found that fibrinogen did in-
hibit 125I-prothrombin binding to HUVEC, but only under
specific cation conditions, i.e., when Mn21 was present.
This result is consistent with the suppression of fibrinogen
binding to purified aVb3 that has been previously reported
(Smith et al., 1994; Suehiro et al., 1996). Thus, competition
between prothrombin and fibrinogen will be determined
by specific microenvironmental cation conditions and the
relative affinity of the two ligands for the receptor. De-
tailed studies are in progress to assess this latter parame-
ter. Also, concentration is not the sole determinant of the
competition between these ligands, e.g., although von
Willebrand factor is present at much lower concentrations
in plasma than fibrinogen, it is still a preferred substrate at
high shear conditions (Savage et al., 1996). In the matrix,
still other conditions will determine the importance of pro-
thrombin, fibrinogen, vitronectin, and other aVb3 ligands
as adhesive substrates. Ultimately, the relative capacity of
these various ligands to support cell migration, as well as
adhesion, will be functionally important. Thus, it is uncer-
tain whether ligand competition will play a significant role
in regulating prothrombin binding to aVb3.
Interaction of prothrombin with aVb3 on intact cells was
not observed unless the cells were stimulated. Such activa-
tion was induced by a well-characterized, model integrin
agonist, PMA. In addition, a physiological agonist, ADP
(Boarder and Hourani, 1998), also activated smooth mus-
cle cells and endothelial cells to adhere to prothrombin.
ADP is a physiologically relevant agonist (Nurden et al.,
1995) for activation of aIIbb3 on platelets, and the second
b3 integrin, aVb3, also responds to this stimulus (Boarder
and Hourani, 1998). Higher concentrations of ADP were
required to activate aVb3 on HUVEC than on HASMC.
This may reflect the higher levels of CD39, an ecto-
ADPase, on HUVEC (Marcus et al., 1997). Three poten-
tial explanations for the effects of these agonists on aVb3
function may be considered. First, PMA stimulation could
increase the number of aVb3 receptors. However, FACS¨
analysis of treated and untreated HUVEC and SMC
showed that expression levels of aVb3 were not changed
upon stimulation. In addition, the induction of adhesion
was observed after short-term treatment by the agonists (1 h
or less), a time insufficient for extensive de novo synthesis.
Second, receptor clustering may enhance ligand binding to
integrins (Miyamoto et al., 1995; Detmers et al., 1987;
Hato et al., 1998). When PMA-stimulated cells were
treated with cytochalasin B at concentrations that inhib-
ited actin cytoskeleton rearrangements as evidenced by
the abolition of cell spreading on prothrombin, cell adhe-
sion to prothrombin was not diminished. This observation
does not exclude a role of integrin clustering in aVb3 acti-
vation. Indeed, we observed that cytochalasin B in the ab-
sence of PMA could induce cell adhesion to prothrombin.
Integrin activation by cytochalasins has been observed by
others (Kucik et al., 1996; Qi et al., 1998) and may arise
from the increased mobility of receptors in the plane of
the membrane. Therefore, aVb3 multimerization may reg-
ulate vascular cell adhesion to prothrombin. Third, PMA
stimulation may change the affinity state of aVb3 for pro-
thrombin. It is well established that integrins can exist in
multiple conformational states (Schwartz et al., 1995; Shat-
til and Ginsberg, 1997), which exhibit distinct functions.
Such affinity modulation is a consequence of inside-out
signaling and is central to the function of aIIbb3 on plate-
lets (Schwartz et al., 1995). Indeed, PMA is one of the ago-
nists that activates aIIbb3 (Shattil and Brass, 1987). Affinity
modulation also has been ascribed to amb2 (Altieri et al.,
1988), a4b1 (Masumoto and Hemler, 1993), a5b1 (Faull et al.,
1993), and a6Ab1 (Delwel et al., 1996). The capacity of
aVb3 to exist in different functional states also has been
previously demonstrated (Bennett et al., 1997) although
the mechanisms underlying these functional differences
were not fully resolved.
PMA induced the conversion of aVb3 from a low- to a
high-affinity/avidity state for prothrombin. The activity of
this agonist suggests that PKC activation may be impor-
tant in the activation of aVb3 (Danilov and Juliano, 1989;
Vuori and Ruoslahti, 1993). This conclusion was sup-
ported by the observation that known inhibitors of PKC,
calphostin C (Kobayashi et al., 1989) and bisindolylmale-
imide I (Toullec et al., 1991), abolished the effect of
PMA on cell adhesion to prothrombin. Calphostin C also
blocked adhesion of HUVEC to prothrombin induced by
Mn21, indicating a role of this cation in activation of PKC.
Thus, the influence of Mn21 on integrin function is not re-
stricted to its effects on the extracellular ligand binding
domains of integrins (Smith et al., 1994). In addition, a sec-
ond intracellular signaling molecule, the neutral protease
calpain, was implicated in the activation pathway of aVb3
based upon the effects of the membrane permeable and
highly potent calpain inhibitor, calpeptin. Calpain can
influence multiple intracellular signaling pathways by
cleaving any of a variety of substrates including PKC,
phospholipase C, pp60 Src, as well as cytoskeletal proteins
including talin and paxillin (Kishimoto et al., 1989; Suzuki
et al., 1992; Al and Cohen, 1993). Indeed, it has been re-
ported that calpain can directly cleave the cytoplasmic tail
of b3-subunit (Du et al., 1995). Thus, the proteolysis of any
one of many potential substrates by calpain could lead to
activation of aVb3, and careful dissection will be required
to identify the requisite event(s). Whereas calpain activity
and integrin function have been previously linked, to date,
the effects of calpain have been assigned to post-ligand
binding events, outside-in signaling (Suzuki et al., 1992;
Cooray et al., 1996). Our results suggest a potential role of
calpain in agonist-induced activation of integrins, inside-
out signaling.
In contrast to prothrombin, HUVEC adhesion to fibrin-
ogen occurred in the absence of added agonists, and PMA
treatment of the cells did not effect aVb3-dependent adhe-
sion to this protein. This observation provides the first di-Byzova and Plow Activated aVb3 Recognition of Prothrombin 2091
rect evidence that different activation states of aVb3 can
discriminate between different ligands. While we cannot
presume that cultured HUVEC necessarily present aVb3
in a resting or basal state, it is clear that these cells adhere
to fibrinogen, with or without additional stimulation,
whereas interaction with prothrombin requires additional
activation of the receptor. This distinction suggest that
aVb3 ligands may be classified as being activation-depen-
dent or as activation-independent. Fibrinogen is an activa-
tion-independent ligand, and prothrombin represents the
activation-dependent ligands. Of note, platelet adhesion
to both prothrombin (Byzova and Plow, 1997) and fibrino-
gen (Savage et al., 1995) does not require activation of
aIIbb3, emphasizing the fine differences in the recognition
specificity of these two b3 integrins.
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